Johnson & Johnson (NYSE:JNJ) Stock Holdings Increased by Jacobs & Co. CA

Jacobs & Co. CA grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 56,569 shares of the company’s stock after purchasing an additional 179 shares during the quarter. Jacobs & Co. CA’s holdings in Johnson & Johnson were worth $8,181,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Bright Futures Wealth Management LLC. grew its holdings in shares of Johnson & Johnson by 2.9% during the second quarter. Bright Futures Wealth Management LLC. now owns 3,389 shares of the company’s stock valued at $495,000 after buying an additional 94 shares in the last quarter. Sachetta LLC grew its holdings in shares of Johnson & Johnson by 5.6% during the second quarter. Sachetta LLC now owns 6,797 shares of the company’s stock valued at $1,097,000 after buying an additional 359 shares in the last quarter. Andra AP fonden grew its holdings in shares of Johnson & Johnson by 144.0% during the second quarter. Andra AP fonden now owns 461,200 shares of the company’s stock valued at $67,409,000 after buying an additional 272,200 shares in the last quarter. Doheny Asset Management CA grew its holdings in shares of Johnson & Johnson by 65.1% during the second quarter. Doheny Asset Management CA now owns 16,327 shares of the company’s stock valued at $2,296,000 after buying an additional 6,437 shares in the last quarter. Finally, First Interstate Bank grew its holdings in shares of Johnson & Johnson by 4.3% during the second quarter. First Interstate Bank now owns 9,260 shares of the company’s stock valued at $1,353,000 after buying an additional 384 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of recent research reports. Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Morgan Stanley boosted their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target for the company. Finally, Bank of America reaffirmed a “neutral” rating and issued a $166.00 price target on shares of Johnson & Johnson in a report on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $174.71.

Johnson & Johnson Trading Up 0.1 %

NYSE:JNJ traded up $0.18 during trading hours on Friday, hitting $142.45. 5,180,236 shares of the stock were exchanged, compared to its average volume of 7,415,524. The company’s 50 day moving average is $150.03 and its two-hundred day moving average is $156.04. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $342.97 billion, a P/E ratio of 20.62, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.66 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.48%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Buying and Selling

In other news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.